ArticleInternational ophthalmology2026
Simultaneous quantification of lifitegrast and Rebamipide in hydrogel-based contact lenses using spectroscopic method.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLifitegrast (LIF) and Rebamipide (REB) are used in effective therapies of dry eye disease (DED). However, conventional eye drops often suffer from poor ocular bioavailability due to rapid pre-corneal clearance and short residence time. Drug-eluting contact lenses have emerged as a promising platform for sustained ocular drug delivery, yet no validated method exists for the simultaneous estimation of LIF and REB in such systems.
objectiveThe present study aimed to develop and validate a simple, robust, and cost-effective UV spectrophotometric method for the simultaneous quantification of LIF and REB in hydrogel-based contact lenses using Vierordt's method.
methodsSimultaneous estimation was carried out in methanol and simulated tear fluid using Vierordt's simultaneous equation approach. The method was validated according to ICH Q2 (R1) guidelines. Drug-loaded hydrogel contact lenses were prepared by free radical polymerization and evaluated for drug content, sterilization-induced leaching, and in-vitro release behavior.
resultsMaximum absorbance was observed at 259 nm for LIF and 229 nm for REB. Calibration curves demonstrated excellent linearity (R
conclusionThe validated UV spectrophotometric method provides a novel and practical analytical tool for the simultaneous estimation of Lifitegrast and Rebamipide in therapeutic contact lenses. Its simplicity and reliability support its translational potential for routine quality control and formulation development in ocular drug delivery for DED.
Indexed as
Identifiers
41790315What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.